Wendy Johnson, managing director of the consultancy, Gemini Advisors, is one of three nominees to the supervisory board of MorphoSys AG, the German antibody therapeutics developer. The other two are Klaus Kühn and Frank Morich. They will replace the long-standing board members Walter Blättler, Daniel Camus and Geoffrey Vernon.
In addition to directing and co-founding Gemini, Ms Johnson is the interim chief operating officer of AmpliPhi BioSciences Corp. Before joining industry she was an assistant director with the Center for Devices and Radiological Health at the US Food and Drug Administration.
Mr Kühn is the former chief financial officer of Bayer AG, and Dr Morich was most recently the chief commercial officer and director at Takeda Pharmaceutical Company Ltd. Shareholders will be asked to approve the nominations on 8 May.
MorphoSys announced the nominations on 30 March 2015.
Copyright 2015 Evernow Publishing Ltd